BioSpace News Archive

Alpha Cognition Inc., a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it will present at the Emerging Growth Conference on April 3, 2024.

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on March 27, 2024.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference.

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

The Company will utilize its proprietary induced pluripotent stem cell (iPSC)-derived NK cells to conduct the evaluation. Subject to the results, Cartherics will then exercise the option to negotiate a commercial license to the IP.

AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, was named to the CDP Supplier Engagement Leaderboard, for the fourth consecutive year.

2seventy bio, Inc., announced that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company’s Board of Directors, effective immediately.

Stevanato Group S.p.A., a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.

Houston, Texas--(Newsfile Corp. - March 20, 2024) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH) has announced the enrollment of the first patient for the clinical trial of its new intra-articular cannabinoid-based injection for knee osteoarthritis.

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.